PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ascpBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleAddiction Science & Clinical Practice
 
Addict Sci Clin Pract. Dec 2007; 4(1): 19–31.
PMCID: PMC2797097
Assessing Addiction: Concepts and Instruments
Sharon Samet, M.S.W., M.Phil.,1,2 Rachel Waxman, B.A.,1 Mark Hatzenbuehler, M.S., M.Phil.,3 and Deborah S. Hasin, Ph.D.1,4,5
1 New York State Psychiatric Institute, New York, New York
2 Columbia University School of Social Work, New York, New York
3 Department of Psychology, Yale University, New Haven, Connecticut
4 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York
5 Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York
CORRESPONDENCE: Sharon Samet, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 123, New York, NY 10032; e-mail: ss1456/at/columbia.edu.
Abstract
Efficient, organized assessment of substance use disorders is essential for clinical research, treatment planning, and referral to adjunctive services. In this article, we discuss the basic concepts of formalized assessment for substance abuse and addiction, as established by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision, and describe six widely used structured assessment instruments. Our aim is to help researchers and clinical programs identify the instruments that best suit their particular situations and purposes.
The appropriate way to assess a substance use disorder depends on the objective. Unstructured clinical interviews serve well enough for many purposes, such as satisfying third-party diagnostic requirements for reimbursement. For many essential clinical and research purposes, however, only structured (scripted) interviews afford sufficient information and reliability. Structured instruments assist treatment planning by providing a standardized comparison of a patient’s characteristics with those of patients who have benefited from interventions in clinical trials. Clinicians also obtain a comprehensive, objective picture of the auxiliary services the patient may need to benefit maximally from treatment. In research, these instruments yield the diagnostic consistency that is indispensable to avoid misclassifying patients and compromising the interpretation of research results.
This article aims to help clinicians and researchers choose the structured assessment instruments appropriate for their needs. For six widely used instruments, we describe the validity and reliability characteristics; administration procedures; training requirements; and advantages and disadvantages based on patient population, treatment orientation, and staff skills. The instruments are the
  • Addiction Severity Index (ASI);
  • Composite International Diagnostic Interview (CIDI);
  • Structured Clinical Interview for DSM-IV (SCID);
  • Alcohol Use Disorders and Associated Disabilities Interview Schedule (AUDADIS);
  • Psychiatric Research Interview for Substance and Mental Disorders (PRISM); and
  • Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA).
figure ASCP-04-1-19-g001
Jess Alford/© 2007 Getty Images
Dr. A. Thomas McLellan, principal developer of the ASI, has often contrasted two patients to illustrate the clinical importance of thorough assessments, such as those yielded by the ASI. One patient, a physician, is severely physiologically addicted to opiates. The other, a young woman, has a milder physiological addiction. An assessment that focuses narrowly on drug abuse history might stop here, leaving the impression that the physician faces the greater challenge to recovery. A more thorough evaluation, however, finds that the physician’s interpersonal relationships, although troubled, are still in place, and he is still working. The young woman, on the other hand, has no social supports except other drug abusers, is unemployed, and has never kept a job for long. In fact, she is the one with greater service needs— in particular, training in social and occupational skills.
In research, an appropriate assessment instrument can make the difference between null and significant findings. A recent review of trials to determine whether tricyclic antidepressants can help substance abusers with comorbid depression provides an illustrative example (Nunes and Levin, 2004). Early trials demonstrated little or no benefit from the medications. These trials admitted patients based on their current depressive symptoms as itemized in instruments such as the Hamilton Depression Scale (Hamilton, 1960) or the Beck Depression Inventory (Beck et al., 1961). Participants would have included some individuals who had comorbid major depression and others who were experiencing transient low moods related to intoxication, withdrawal, or stress reactions. More recent studies, in contrast, admitted only individuals who met formal diagnostic criteria for major depressive disorder, which include persistent symptoms over a period of time. Some recent studies also delayed assessment until candidates had been abstinent for a week to ensure that they were past withdrawal. In these more uniform populations, the medications consistently alleviated patients’ depression and also modestly improved their substance abuse outcomes.
The assessment instruments we will discuss, with the exception of the ASI, all elicit the information required to diagnose substance use disorders and other psychiatric disorders according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV; American Psychiatric Association, 2000). Those criteria, the product of more than 30 years of development and testing, now set the standard for both research and clinical assessment (see “The DSM and Standardized Assessment”). Where the instruments differ is in
  • Format—that is, whether they are fully structured or semi-structured;
  • The particular clinical or research objectives they can serve;
  • Reliability and validity for selected uses (see “Reliability and Validity”);
  • Convenience features, such as modularity and availability in computer-based formats; and
  • Training requirements.
Fully Structured Versus Semi-Structured Formats
A fully structured assessment instrument is a script. It specifies the questions the interviewer is to ask, exactly as written, as well as a choice of responses for the interviewee. When asking the questions, the interviewer skips some, based on patient characteristics or previous responses, and avoids adding probes of his or her own. A semi-structured instrument similarly lists questions to be read verbatim, but also allows the interviewer to add followup queries based on his or her clinical interpretation of the interviewee’s initial response.
Both formats have advantages and disadvantages. Fully structured interviews are economical. They require no clinical judgment, so trained lay interviewers can administer them. They generally take less time to administer. Many large research studies and large treatment facilities use fully structured instruments, because staff members with little experience can perform the initial and followup assessments. Semi-structured interviews, in contrast, through their open-ended probes, provide greater detail on the client’s status.
Convenience Features
Many assessment instruments are modular, permitting flexibility in the choice of sections used and diagnoses assessed. Thus, for example, researchers or clinicians who do not encounter psychotic individuals because of program regulations or a research protocol may omit a psychosis module.
Several structured and semi-structured diagnostic interviews are available in computer-assisted formats. Interviewers read questions to interviewees and enter responses into a computer rather than a paper form. This reduces administration time and rater error, as the program automatically skips or adjusts the wording of questions based on patients’ previous responses. Further, computerized administration saves many hours of data entry and avoids the errors that can occur in transferring data from paper into a computer database for analysis. Computerizing the logic of the interview also reduces the need for post-interview data cleaning. The data go directly into a database that can immediately generate reports and statistics.
Of the instruments we discuss here, the ASI and CIDI make up the common assessment battery of the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN), which conducts studies to evaluate evidence-based treatment interventions in widely diverse community-based treatment settings and patient populations nationwide. Prior to adopting these measures, a CTN workgroup evaluated many measures for reliability, validity, efficiency, and suitability for widespread use in nonresearch settings.
RELIABILITY AND VALIDITY
An instrument’s reliability and validity are critical to its value. All the instruments discussed in this article are highly reliable and valid, but the extent of their reliability or validity may differ in particular situations.
Reliability
The question of reliability is: Will users of the instrument consistently reach the same diagnostic conclusions? A straightforward and rigorous way to answer this question is the test-retest method. Two or more clinicians use the instrument to conduct independent assessments of the same patient, and the degree of correlation among their findings is calculated. The standard statistical measure of the degree of the clinicians’ agreement, the kappa coefficient, equals 1 if agreement is complete and less than zero when agreement is no greater than chance might produce (Cohen, 1960). Generally, a test-retest kappa score of 0.75+ indicates excellent reliability; 0.60 to 0.74 is good; 0.40 to 0.59 is fair; and less than 0.40 is poor (Fleiss, 1981).
Validity
The question of validity is: Does the instrument truly and unambiguously assess the condition it is designed to evaluate? This question has more dimensions than the estimation of reliability; accordingly, validity is estimated with a number of methods.
The widely used SCID was the first standardized psychiatric interview based on the DSM and has been updated to correspond to the most current DSM criteria. The AUDADIS, PRISM, and SSADDA were specifically designed for substance abuse research, but are adaptable for clinical purposes, too.
Brief descriptions of these instruments follow. For a summary comparison of their properties, see Table 1.
TABLE 1
TABLE 1
Characteristics and Selected Assessment Categories of Six Structured Assessment Instruments
The Addiction Severity Index
The ASI (McLellan et al., 1980, 1992) screens for problems and impairments that commonly accompany drug abuse and dependence. These include, among others, interpersonal difficulties with family, friends, and co-workers; medical conditions such as hepatitis B and C, HIV/AIDS, sexually transmitted diseases, alcoholic liver disease, acute myocardial infarction, pneumonia, and metabolic and endocrine complications (Kresina et al., 2004; Mertens et al., 2003); and legal troubles. The ASI provides information that clinicians can use to address these problems with appropriate interventions or referrals.
The semi-structured ASI evaluates patients’ functioning and lifetime experiences in seven domains: (1) medical conditions, (2) employment/support, (3) use of alcohol and drugs, (4) legal issues, (5) family history, (6) family/social relationships, and (7) psychiatric disorders. The administrator asks the patient to rate his or her level of distress in each domain during the past 30 days from 0 (none) to 4 (extreme) and independently rates the patient’s need for treatment in each domain from 0 (none necessary) to 9 (treatment needed to intervene in a life-threatening situation). Finally, the administrator calculates a composite score from a subset of the distress and treatment need responses. This score becomes the basis for treatment planning. Altogether, the ASI takes approximately 45 to 60 minutes to administer, plus 10 to 20 minutes for post-interview scoring.
THE DSM AND STANDARDIZED ASSESSMENT
The year 1980 saw the publication of an epochal document in psychiatry: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition (DSM-III; American Psychiatric Association, 1980). The DSM-III provided clinicians and researchers with standardized definitions and diagnostic criteria for more than 200 psychiatric disorders, including substance abuse and dependence disorders. Prior to this publication, clinicians and researchers commonly used the same diagnostic terms to mean different things, and clinicians often disagreed on whether patients had specific disorders (Spitzer, Endicott, and Robins, 1975; Spitzer and Fleiss, 1974). Substance abuse professionals engaged in semantic debates over the definition of addiction—even over the very existence of such a condition.
Following the publication of the DSM-III, diagnostic criteria were included in the mental disorders section of the International Classification of Diseases, 10th Edition (ICD-10; World Health Organization, 1993). The ICD-10 is widely used outside the United States to define psychiatric diagnoses.
Substance Use Disorders in DSM-IV
The current edition of the DSM, DSM-IV-TR, sets diagnostic criteria for two types of substance use disorder: dependence and abuse. Some patients seeking treatment report too few symptoms to meet the criteria for either diagnosis. In these cases, the specific symptoms, symptom clusters, and the severity of associated problems can inform effective strategies for intervention and management.
The ICD-10 criteria for substance dependence are similar to those of the DSM-IV. The ICD-10 counterpart to abuse is called “harmful use” and is less specific.
Substance Dependence
Drug or alcohol dependence is diagnosed by documenting that a patient has experienced at least three of seven criteria for a particular substance within a 12-month period. The criteria are:
  • Tolerance
  • Withdrawal
  • Substance often taken in larger amounts or over longer period than intended
  • Persistent desire or unsuccessful efforts to cut down or control use
  • Great deal of time spent in activities necessary to obtain, use, or recover from the substance
  • Important social, occupational, or recreational activities given up or reduced
  • Continued use despite knowledge of having a persistent or recurrent physical or psychological problem likely to have been caused or exacerbated by the substance
Although the DSM-IV provides no standards for dependence severity, clinicians may specify “with physiological dependence” or “with withdrawal” to indicate the presence of tolerance (i.e., the need for higher doses to achieve intoxication or other desired effects). Withdrawal, in particular, predicts medical problems and poor outcome (Hasin et al., 2000; Schuckit et al., 2003). Alternatively, a symptom or criteria count can function as a measure of dependence severity (Hasin et al., 2006b).
The DSM-IV lists substance-specific intoxication and withdrawal symptoms for most of the common classes of drugs. Two exceptions are hallucinogens and cannabis, neither of which had a known withdrawal syndrome at the time of the document’s publication. Planners for the DSM-V are considering the addition of a withdrawal syndrome for cannabis. In anticipation of such a potential change, the CIDI and AUDADIS interviews contain items related to possible marijuana withdrawal.
Test-retest studies have repeatedly shown good to excellent reliability for the diagnosis of substance dependence with the DSM-IV (Bucholz et al., 1995; Chatterji et al., 1997; Easton et al., 1997; Grant et al., 1995, 2003; Hasin et al., 1996, 1997a; Horton, Compton, and Cottler, 2000; Williams et al., 1992). The DSM-IV substance dependence diagnosis also shows good validity in two forms of multi-method comparisons. One compares ICD-10, DSM-IV, and DSM-III-R diagnoses obtained from a single diagnostic interview (Grant, 1993; Hasin et al., 1997b; Schuckit et al., 1994). The other compares diagnoses from a single system (such as DSM-IV) produced by different diagnostic interviews (Cottler et al., 1997; Pull et al., 1997).
Studies of families with alcohol problems have validated the criteria for the substance dependence diagnosis. A family history of alcohol problems is strongly associated with DSM-IV alcohol dependence (Hasin et al., 1997c; Hasin and Paykin, 1999). In addition, animal models support the validity of many elements of dependence (Robinson, 2004; Tapper et al., 2004), and neuroscientists and geneticists are finding links to biological variations that increase or reduce the risk for dependence (e.g., Edenberg et al., 2004; Hogg and Bertrand, 2004).
Substance Abuse
Patients who do not meet the criteria for substance dependence may be diagnosed with substance abuse if they report experiencing one or more of four abuse symptoms repeatedly over a 12-month period. The symtoms are:
  • Failure to fulfill major obligations at work, school, or home
  • Recurrent use in situations in which it is physically hazardous
  • Recurrent substance-related legal problems
  • Continued use despite persistent social or interpersonal problems
Many clinicians have questioned the separation of substance dependence and substance abuse. Studies have shown that the DSM criteria for abuse are less valid than those for dependence. However, these studies diagnosed substance abuse hierarchically, meaning that an abuse diagnosis was considered to be redundant if dependence was present. Although DSM-IV stipulates this procedure, not everyone with dependence also meets the criteria for abuse (Hasin and Grant, 2004). Women and minorities appear especially likely to experience dependence without abuse (Hasin et al., 2005; Hasin and Grant, 2004). Studies that assessed abuse regardless of whether dependence was present showed better reliability for the criteria for abuse (Bucholz et al., 1995; Canino et al., 1999; Cottler et al., 1997; Pull et al., 1997). In summary, the DSM-IV hierarchical status of abuse is problematic, but the criteria yield reliable diagnoses.
DSM-IV and Substance Use Comorbidity
Extensive comorbidity between substance use disorders and other psychiatric disorders has been reported consistently in patients (Nunes, Hasin, and Blanco, 2004) as well as in the general population (Grant et al., 2004a, 2004b; Regier et al., 1990). Such comorbidity can be serious. For example, studies with acceptable response rates (70 percent or more) and reliable diagnostic assessments have consistently found an adverse effect of major depression on the outcome of substance use disorders (Hasin, Nunes, and Meydan, 2004). Further, among patients with histories of substance dependence and major depression, the occurrence of a major depressive episode during periods of sustained abstinence predicts a higher number of suicide attempts (Aharonovich et al., 2002).
To be accurate, assessments must address the fact that substance intoxication and withdrawal can mimic symptoms of depression, psychosis, or other independent psychiatric disorders. Accordingly, the DSM-IV distinguishes among “expected effects” of substance intoxication or withdrawal, “primary disorders,” and “substance-induced disorders.” A primary disorder is diagnosed if “the symptoms are not due to the direct physiological effects of a substance” (American Psychiatric Association, 2000). Psychiatric disorders that co-occur with substance intoxication or withdrawal can be considered primary if (1) symptoms substantially exceed the expected effects of the substance in the amount that was used; (2) there is a personal history of psychiatric symptoms during periods of extended abstinence; (3) the onset of psychiatric symptoms clearly preceded the onset of substance use; and (4) symptoms persisted for at least a month after the cessation of intoxication or withdrawal. Symptoms that are not considered primary fall into the category either of expected effects of a substance or of a substance-induced disorder that exceeds intoxication or withdrawal effects and deserves independent clinical attention. Instrument developers have incorporated this information into some tools, in particular the SSADDA and PRISM.
The ASI’s psychometric properties have been tested extensively (Alterman et al., 1994; Hodgins and el-Guebaly, 1992; Joyner, Wright, and Devine, 1996; Kosten, Rounsaville, and Kleber, 1983; McLellan et al., 1985; Rogalski, 1987). Several studies have demonstrated good to excellent reliability and validity for the instrument (Butler et al., 2001; Hendriks et al., 1989; Leonhard et al., 2000; Weisner, McLellan, and Hunkeler, 2000). A 2004 summary of studies in multiple patient groups (Mäkelä) found that the reliability of composite scores varied from high (Daeppen et al., 1996; McLellan et al., 1985; Peters et al., 2000) to low (Drake, McHugo, and Biesanz, 1995; Zanis et al., 1994; Zanis, McLellan, and Corse, 1997). Three of the seven ASI domains (medical conditions, use of alcohol, and psychiatric disorders) have high internal consistency across studies, while the other four are more variable. Correlations between domains are usually low, except those between the drug and legal measures and those between the psychiatric and social impairment measures. The lack of across-the-board correlations is consistent with the ASI’s perspective, which is that impairment in some domains does not necessarily entail impairment in others.
The ASI, by itself, may not be a highly reliable screen for special populations, such as the homeless or dually diagnosed. For the latter groups, the ASI should be supplemented with instruments that assess comorbidity in greater depth, such as the PRISM or the SSADDA.
Interviewer training and experience enhance the validity of ASI results (Mäkelä, 2004). Standardized training is available and consists of a 2-day classroom component and materials for independent study (see www.tresearch.org/training/asi_train.htm).
Many community programs include the ASI in their initial assessment battery, but informal reports suggest that some look upon it as merely required paperwork and use its information minimally, if at all, in treatment. To remedy this situation, the NIDA/Substance Abuse and Mental Health Services Administration (SAMHSA) Blending Initiative has produced a curriculum on transforming ASI data into clinically useful information (see www.nida.nih.gov/Blending/ASI.html).
Alcohol Tolerance Item From the World Mental Health Composite International Diagnostic Interview (WMH-CIDI)
ALCOHOL DEPENDENCE
Did you ever need to drink a larger amount of alcohol to get an effect, or did you ever find that you could no longer get a “buzz” or a high on the amount you used to drink?YESNODKRF
(1)(5)(8)(9)
Source: Kessler and Ustün, 2004. Abbreviations: DK, don’t know; RF, refused.
Numbers are codes for recording the four responses.
The Composite International Diagnostic Interview
The CIDI, originally developed by the World Health Organization, assesses 22 DSM-IV diagnoses, including mood, anxiety, and substance use disorders (see “Alcohol Tolerance Item From the World Mental Health Composite International Diagnostic Interview (WMH-CIDI)”). For each substance use disorder, the CIDI elicits other information useful for treatment planning, such as the patterns and course of alcohol and drug use. The fully structured instrument takes approximately 120 minutes to administer in its entirety (Kessler and Ustün, 2004).
Various versions and adaptations of the original CIDI have been developed. The University of Michigan version, the UM-CIDI, has been used in a large international epidemiological survey (Wittchen and Kessler, 1994), but appears to produce lower prevalence estimates than other diagnostic instruments (Wittchen et al., 1998). To address this problem and others related to earlier versions of the CIDI, the World Mental Health Survey Initiative Version, the WMH-CIDI, was developed (Kessler and Ustün, 2004). A complete description of WMH-CIDI modifications is reported elsewhere (Kessler and Ustün, 2004). The WMH-CIDI is available in paper and computerized forms for download or computer-assisted administration at www.hcp.med.harvard.edu/wmhcidi/instruments.php.
Programs or projects may use the CIDI substance use sections alone or combine them with other sections to achieve the desired range of assessment. To meet the particular needs of the substance abuse field, researchers have developed the CIDI Substance Abuse Module (CIDI-SAM), an expanded version of the original CIDI substance use section that elicits detailed information on such areas as the onset and history of substance abuse, withdrawal symptoms, common comorbidities, social consequences, and treatment history (Cottler, Robins, and Helzer, 1989; Horton, Compton, and Cottler, 2000; epi.wustl.edu/epi/assessments/sam.htm).
Test-retest studies of the original CIDI and the CIDI-SAM paper versions have demonstrated good to excellent reliability for DSM-IV diagnoses of any substance use disorder or substance dependence and fair to good reliability for abuse (Rubio-Stipec, Peters, and Andrews, 1999; Wittchen et al., 1998). The reliability of the CIDI, version 3.0, was tested in the WHO World Mental Health Surveys by comparing CIDI-derived diagnoses to those derived with the SCID (Haro et al., 2006). Concordance for alcohol dependence (with or without abuse) was excellent; concordance for drug dependence (with or without abuse) was fair; and concordance for alcohol abuse and drug abuse was good.
NIDA’s CTN adopted the CIDI after comparing five commonly used substance use disorder diagnostic instruments on 26 criteria, including psychometric properties, diagnostic time frames, time to administer, and training and financial considerations (Forman et al., 2004). The CTN workgroup ultimately determined that only the CIDI met three crucial CTN requirements: it can be administered by trained research technicians with no prior clinical experience; it provides for DSM-IV, as well as International Classification of Diseases, 10th Edition (ICD-10; World Health Organization, 1993), substance use disorder diagnoses; and it provides for past-year and lifetime diagnoses. At this point, it is too soon to know whether CTN-related community-based programs will adopt the CIDI for clinical use.
Alcohol Use Screening From the Structured Clinical Interview for DSM (SCID)
ALCOHOL USE SCREENING
What are your drinking habits like?
 How much do you drink?
 Has there ever been a time in your life when you had five or more drinks on one occasion?
When in your life were you drinking the most?
 How long did that period last?
During that time…
 How often were you drinking?
 What were you drinking? How much?
During that time…
 Did your drinking cause problems for you?
 Did anyone object to your drinking?
The Structured Clinical Interview for DSM-IV
The SCID is available in different versions for researchers and clinicians. Additionally, the research version is available in formats for patients, nonpatients, and patients with psychotic disorders. The Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (First et al., 2002), provides lifetime and current diagnostic assessments for many DSM-IV disorders, including substance use disorders. The separate SCID for Axis II disorders provides the basis for diagnosing personality disorders (First et al., 1997).
The semi-structured SCID is designed for administration by interviewers with clinical expertise, but research assistants having extensive experience with a population under study have sometimes learned to administer it successfully. After an open-ended overview and brief general screening, the interviewer takes the patient through the questions on the form, following up as needed (based on clinical judgment) to clarify responses. The alcohol and drug modules contain open-ended screening questions as well (see “Alcohol Use Screening From the Structured Clinical Interview for DSM (SCID)”). Administration can take up to several hours, depending on the complexity of the patient’s substance and psychiatric history. The instrument is modular, so clinicians can make use of only those sections that pertain to assessment aims. It contains a minimal number of nondiagnostic items to keep administration time as brief as possible.
In tests among substance-abusing populations, the SCID has demonstrated excellent reliability for diagnosing DSM-III-R substance dependence (American Psychiatric Association, 1987; Ross et al., 1995). A small test-retest study of 52 patients with DSM-IV diagnoses showed excellent reliability for substance use disorders (Zanarini et al., 2000). The SCID Web site (www.scid4.org/index.html) provides information on the different versions, psychometric properties, ways to obtain copies of the interview and training materials, and procedures for arranging on-site training. A user’s guide provides basic training in the use of the SCID. In addition, an 11-hour videotape training program is available with examples of interviews with actual patients. The instrument’s developers recommend at least 20 hours of training on the full SCID for most clinicians. A Spanish-language version of the SCID (research version), in which only the questions have been translated, and a computer-assisted SCID (for Axis I disorders, clinician version), developed by an outside source, can be obtained through the SCID Web site.
The Alcohol Use Disorder and Associated Disabilities Interview Schedule
The AUDADIS (Grant et al., 1995, 2003) provides for current (last 12 months) and lifetime DSM-IV diagnoses of major mood, anxiety, personality, and substance use disorders. Originally developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for use in population-based epidemiological surveys, the fully structured AUDADIS functions as an economical tool that lay staff in treatment programs can administer for intake screening. Clinicians can use the detailed descriptive data obtained by the AUDADIS to structure treatment based on a patient’s specific substance-related behaviors. In addition to alcohol, tobacco, and other drug use, modules address treatment and family history. Numerous queries address the frequency and quantity of use of each type of alcohol (e.g., beer, wine, liquor) and each illicit drug during three time periods—that of heaviest use, the past 12 months, and the interviewee’s lifetime (see “Sample Item From the Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS)”).
The AUDADIS showed high reliability in a test-retest study in clinical settings where comorbidity was expected to be high (Hasin et al., 1996). Its test-retest reliabilities for alcohol and drug consumption, abuse, and dependence, as well as those for other modules, were good to excellent (Grant et al., 1995, 2003). The AUDADIS interview can be downloaded (niaaa.census.gov/questionaire.html). The instrument’s developers recommend using the computer-assisted version.
The Psychiatric Research Interview for Substance and Mental Disorders
The PRISM (Hasin et al., 1996, 2006a; Hasin, Trautman, and Endicott, 1998) is a semi-structured diagnostic interview designed expressly for assessing comorbid psychiatric disorders in individuals who abuse substances. The instrument’s strength is in differentiating independent psychiatric disorders, such as depression, from the effects of intoxication and withdrawal. Along with abuse and dependence diagnoses for specific substance categories, clinicians and researchers can use the PRISM to make current and lifetime DSM-IV diagnoses of Axis I and Axis II disorders that commonly occur with substance abuse, such as mood, anxiety, and psychotic disorders.
The PRISM sections on substance use disorders are placed at the beginning of the interview and provide a background for the overall clinical picture. Periods of chronic intoxication (defined as “at least 4 days a week for a month”) or binge use (defined as “most of the day for 3 or more days”) and extended periods of abstinence are identified and charted on a timeline. The timeline is the only part of the PRISM that is conducted in an unstructured format, and timeline information is not coded for data entry. The purpose of the timeline is to assist in differentiating primary versus substance-induced symptoms in later diagnostic sections.
PRISM developers incorporated two features into the instrument to avoid the lengthy administration time associated with many standardized interviews. First, diagnostic sections are modular, so the instrument can be tailored to fit specific treatment or research needs. Second, consumption questions in the substance use module do not seek detailed information about patterns, but simply ask how often the interviewee has used the substance “in the last 12 months” or “ever” and whether the individual has ever experienced a period of chronic intoxication or binge use. If the response to any of these broad questions is “yes,” the interviewer moves on to the abuse and dependence diagnostic module.
A recent test-retest study of 285 heavy substance users showed good to excellent reliability for most dependence diagnoses, including alcohol, cocaine, heroin, cannabis, and sedative dependence (Hasin et al., 2006a). An independently conducted validity study of a Spanish-language version of the PRISM with the Longitudinal, Expert, All-Data Diagnosis (LEAD) procedure (Spitzer, 1983) as the “gold standard” and the SCID found that the concordance of the three assessments in substance dependence was good to excellent. However, PRISM/LEAD concordance was significantly better than SCID/LEAD concordance on current cannabis and cocaine dependence, as well as past alcohol abuse and dependence (Torrens et al., 2004). The English version of the PRISM can be downloaded, together with training information (www.columbia.edu/~dsh2/prism). A computer-assisted version, which will include questions on marijuana withdrawal and modules for nicotine-related disorders, pathological gambling, and attention deficit hyperactivity disorder, will be available in 2008.
Sample Item From the Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS)
Now I’d like to ask you about drinking beer.

5a. During the last 12 months, did you drink any beer, light beer or malt liquor? Do not count nonalcoholic beers. Statement D
1 — Yes
2 — No - SKIP to Statement E, page 11
5b. (SHOW FLASHCARD 12)
During the last 12 months, about how often did you drink any beer or malt liquor?
1 __ Everyday
2 __ Nearly every day
3 __ 3 to 4 times a week
4 __ 2 times a week
5 __ Once a week
6 __ 2 to 3 times a month
7 __ Once a month
8 __ 7 to 11 times in the last year
9 __ 3 to 6 times in the last year
10 __ 1 or 2 times in the last year
The Semi-Structured Assessment for Drug Dependence and Alcoholism
The SSADDA (Pierucci-Lagha et al., 2005) was developed for use in studies of genetic influences on cocaine and opioid dependence. Derived from the Semi-Structured Assessment for the Genetics of Alcoholism, the SSADDA provides extensive coverage of the physical, psychological, social, and psychiatric manifestations of cocaine and opioid abuse and dependence in addition to a number of related Axis I and Axis II disorders. A standout feature of the SSADDA is its inclusion of questions about the onset and recency of individual alcohol and drug symptoms, permitting a temporal assessment of symptom clusters. Information about the timing of symptoms is particularly helpful in distinguishing comorbid disorders from intoxication or withdrawal effects.
The reliability of individual dependence criteria in the SSADDA has been tested to determine the extent to which independent interviewers arrive at the same diagnostic conclusions. Overall, the inter-rater reliability estimates were excellent for individual DSM-IV criteria for nicotine and opioid dependence; good for alcohol and cocaine dependence; and fair for dependence on cannabis, sedatives, and stimulants (Pierucci-Lagha et al, 2007). A computer-assisted version of the SSADDA is available free. Further information can be obtained by contacting Dr. Amira Pierucci-Lagha, Alcohol Research Center, Department of Psychiatry, University of Connecticut School of Medicine.
figure ASCP-04-1-19-g002
Zigy Kaluzny/© 2007 Getty Images
The publication of the DSM-III ushered in a period of standardized assessment and diagnosis in mental health research. Several widely used structured and semi-structured instruments for assessing dependence, co-occurring psychiatric disorders, and associated problems have shown good reliability, validity, and acceptance in clinical research settings. These instruments are now being used in community settings to inform treatment planning and case management.
Regardless of their original purposes, all of the measures described in this paper can be used for both research and treatment. The decision to use one instrument rather than another will depend on a number of practical considerations. Reliability and validity often vary considerably between specific drug categories. Thus, a review of the strength of the specific drug diagnoses of interest is important. Users will need to consider whether disorders other than substance use or other characteristics of interest are covered and, when necessary, if the instrument is available in a language other than English. Staff level of experience and training costs are also key factors in evaluating the appropriateness of an instrument for a particular research or treatment setting.
Most of the measures are in modular format. Substance disorder and other modules, along with a measure of problem severity like the ASI, can serve as the basis of a thorough intake interview and, as the patient progresses through treatment, can be used to assess changes in status systematically. Modules from different instruments can be combined, but this can be complicated if computer-assisted versions are used. In addition, even the most user-friendly computer-assisted instruments require staff with technical know-how, and computer and software costs and licensing fees can be high in relation to budget allowances. Conversely, paper-and-pencil versions consume additional staff time for data cleaning and data entry, require repeated printing, and can take up a great deal of storage space, depending on the sample or patient population size. Thus, a thorough cost estimate is needed before deciding whether to use a paper-and-pencil or computerized format.
ACKNOWLEDGMENTS
Support is acknowledged from NIAAA grants K05 AA014223 and R01 DA10919, NIDA grant U10 DA130350B2, and the New York State Psychiatric Institute. The authors wish to thank Ms. Valerie Richmond for editorial assistance and manuscript preparation.
  • Aharonovich E, et al. Suicide attempts in substance abusers: Effects of major depression in relation to substance use disorders. American Journal of Psychiatry. 2002;159(9):1600–1602. [PubMed]
  • Aharonovich E, et al. Postdischarge cannabis use and its relationship to cocaine, alcohol, and heroin use: A prospective study. American Journal of Psychiatry. 2005;162(8):1507–1514. [PubMed]
  • Alterman AI, et al. Interviewer severity ratings and composite scores of the ASI: A further look. Drug and Alcohol Dependence. 1994;34(3):201–209. [PubMed]
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3d ed. Washington, DC: American Psychiatric Association; 1980.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3d ed. Washington, DC: American Psychiatric Association; 1987. Text Revision; DSM-III-R.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000. Text Revision; DSM-IV-TR.
  • Beck AT, et al. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:53–63.
  • Bucholz KK, et al. Reliability of individual diagnostic criterion items for psychoactive substance dependence and the impact on diagnosis. Journal of Studies on Alcohol. 1995;56(5):500–505. [PubMed]
  • Budney AJ, et al. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Archives of General Psychiatry. 2001;58(10):917–924. [PubMed]
  • Butler SF, et al. Initial validation of a computer-administered Addiction Severity Index: The ASI-MV. Psychology of Addictive Behaviors. 2001;15(1):4–12. [PubMed]
  • Canino G, et al. The Spanish Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): Reliability and concordance with clinical diagnoses in a Hispanic y population. Journal of Studies on Alcohol. 1999;60(6):790–799. [PubMed]
  • Chatterji S, et al. Reliability of the alcohol and drug modules of the Alcohol Use Disorder and Associated Disabilities Interview Schedule–Alcohol/Drug-Revised (AUDADIS–ADR): An international comparison. Drug and Alcohol Dependence. 1997;47(3):171–185. [PubMed]
  • Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement. 1960;20:37–46.
  • Cottler LB, et al. Concordance of DSM-IV alcohol and drug use disorder criteria and diagnoses as measured by AUDADIS-ADR, CIDI and SCAN. Drug and Alcohol Dependence. 1997;47(3):195–205. [PubMed]
  • Cottler LB, Robins LN, Helzer JE. The reliability of the CIDI-SAM: A comprehensive substance abuse interview. British Journal of Addiction. 1989;84(7):801–814. [PubMed]
  • Crowley TK, et al. Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug and Alcohol Dependence. 1998;50(1):27–37. [PubMed]
  • Daeppen JB, et al. Validation of the Addiction Severity Index in French-speaking alcoholic patients. Journal of Studies on Alcohol. 1996;57(6):585–590. [PubMed]
  • Drake RE, McHugo GJ, Biesanz JC. The test-retest reliability of standardized instruments among homeless persons with substance use disorders. Journal of Studies on Alcohol. 1995;56(2):161–167. [PubMed]
  • Easton C, et al. Test-retest reliability of the alcohol and drug use disorder sections of the schedules for clinical assessment in neuropsychiatry (SCAN) Drug and Alcohol Dependence. 1997;47(3):187–194. [PubMed]
  • Edenberg HJ, et al. Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. American Journal of Human Genetics. 2004;74(4):705–714. [PubMed]
  • First MB, et al. Structured Clinical Interview for DSM-IV Personality Disorders, (SCID-II) Washington, DC: American Psychiatric Press; 1997.
  • First MB, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition, SCID-I/P. New York: Biometrics Research, New York State Psychiatric Institute; 2002.
  • Fleiss JL. Statistical Methods for Rates and Proportions. 2d ed. New York: John Wiley & Sons; 1981.
  • Forman RF, et al. Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment. 2004;27(1):1–8. [PMC free article] [PubMed]
  • Grant BF. Comparison of DSM-III-R and draft DSM-IV alcohol abuse and dependence in a general population sample. Addiction. 1993;88(12):1709–1716. [PubMed]
  • Grant BF, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): Reliability of al alcohol and drug modules in a general population sample. Drug and Alcohol Dependence. 1995;39(1):37–44. [PubMed]
  • Grant BF, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): Reliability of alcohol consumption, tobacco use, family history of depression and psychiatric modules in a general population sample. Drug and Alcohol Dependence. 2003;71(1):7–16. [PubMed]
  • Grant BF, et al. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry. 2004a;61(4):361–368. [PubMed]
  • Grant BF, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry. 2004b;61(8):807–816. [PubMed]
  • Grant BF, Stinson FS, Harford TTC. The 5-year course of alcohol abuse among young adults. Journal of Substance Abuse. 2001;13(3):229–238. [PubMed]
  • Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56–62. [PMC free article] [PubMed]
  • Haro JM, et al. Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. International Journal of Methods in Psychiatric Research. 2006;15(4):167–180. [PubMed]
  • Hasin DS, et al. Psychiatric Research Interview for Substance and Mental Disorders: Reliability for substance abusers. American Journal of Psychiatry. 1996;153(9):1195–1201. [PubMed]
  • Hasin DS, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): Reliability of alcohol and drug modules in a clinical sample. Drug and Alcohol Dependence. 1997a;44(2–3):133–141. [PubMed]
  • Hasin DS, et al. Nosological comparisons of alcohol and drug diagnoses: A multisite, multi-instrument international study. Drug and Alcohol Dependence. 1997b;47(3):217–226. [PubMed]
  • Hasin DS, et al. Alcohol dependence and abuse diagnoses: Validity in community sample heavy drinkers. Alcoholism: Clinical and Experimental Research. 1997c;21(2):213–219. [PubMed]
  • Hasin DS, et al. Differentiating DSM-IV alcohol dependence and abuse by course: Community heavy drinkers. Journal of Substance Abuse. 1997d;9:127–135. [PubMed]
  • Hasin DS, et al. Withdrawal and tolerance: Prognostic significance in DSM-IV alcohol dependence. Journal of Studies on Alcohol. 2000;61(3):431–438. [PubMed]
  • Hasin DS, et al. Co-occurring DSM-IV drug abuse in DSM-IV drug dependence: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug and Alcohol Dependence. 2005;80(1):117–123. [PubMed]
  • Hasin DS, et al. Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. American Journal of Psychiatry. 2006a;163(4):689–696. [PubMed]
  • Hasin DS, et al. DSM-IV alcohol dependence: A categorical or dimensional phenotype? Psychological Medicine. 2006b;36(12):1695–1705. [PubMed]
  • Hasin DS, Grant BF. The co-occurrence of DSM-IV alcohol abuse in DSM-IV alcohol dependence: Results of the National Epidemiologic Survey on Alcohol and Related Conditions on heterogeneity that differ by population subgroup. Archives of General Psychiatry. 2004;61(9):891–896. [PubMed]
  • Hasin DS, Grant BF, Endicott J. The natural history of alcohol abuse: Implications for definitions of alcohol use disorders. American Journal of Psychiatry. 1990;147(11):1537–1541. [PubMed]
  • Hasin DS, Nunes E, Meydan J. Comorbidity of alcohol, drug and psychiatric disorders: Epidemiology. In: Kranzler HR, Tinsley JA, editors. Dual Diagnosis and Treatment: Substance Abuse and Comorbid Disorders. New York: Marcel Dekker; 2004. pp. 1–34.
  • Hasin DS, Paykin A. Alcohol dependence and abuse diagnoses: Concurrent validity in a nationally representative sample. Alcoholism: Clinical and Experimental Research. 1999;23(1):144–150. [PubMed]
  • Hasin DST, Trautman K, Endicott J. Psychiatric research interview for substance and mental disorders: Phenomenologically based diagnosis in patients who abuse alcohol logically or drugs. Psychopharmacology Bulletin. 1998;34(1):3–8. [PubMed]
  • Hendriks VM, et al. The Addiction Severity Index: Reliability and validity in a Dutch addict population. Journal of Substance Abuse and Treatment. 1989;6(2):133–141. [PubMed]
  • Hodgins DC, el-Guebaly Guebaly N. More data on the Addiction Severity Index: Reliability and validity with the mentally ill substance abuser. Journal of Nervous and Mental Disease. 1992;180(3):197–201. [PubMed]
  • Hogg RC, Bertrand D. What genes tell us about nicotine addiction. Science. 2004;306(5698):983–985. [PubMed]
  • Horton J, Compton W, Cottler LB. Reliability of substance use disorder diagnoses among African-Americans and Caucasians. Drug and Alcohol Dependence. 2000;57(3):203–209. [PubMed]
  • Joyner LM, Wright JD, Devine JA. Reliability and validity of the Addiction Severity Index among homeless substance misusers. Substance Use and Misuse. 1996;31(6):729–751. [PubMed]
  • Kessler RC, Ustün TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI) International Journal of Methods in Psychiatric Research. 2004;13(2):93–121. [PubMed]
  • Kosten TR, Rounsaville BJ, Kleber HD. Concurrent validity of the Addiction Severity Index. Journal of Nervous and Mental Disease. 1983;171(10):606–610. [PubMed]
  • Kresina TF, et al. Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities. Clinical Infectious Diseases. 2004;38(Suppl 5):S398–S401. [PubMed]
  • Leonhard C, et al. The Addiction Severity Index: A field study of internal consistency and validity. Journal of Substance Abuse and Treatment. 2000;18(2):129–135. [PubMed]
  • Mäkelä K. Studies of the reliability and validity of the Addiction Severity Index. Addiction. 2004;99(4):398–410. discussion 411–418. [PubMed]
  • McLellan AT, et al. An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous and Mental Disease. 1980;168(1):26–33. [PubMed]
  • McLellan AT, et al. New data from the Addiction Severity Index: Reliability and validity in three centers. Journal of Nervous and Mental Disease. 1985;173(7):412–423. [PubMed]
  • McLellan AT, et al. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse and Treatment. 1992;9(3):199–213. [PubMed]
  • Mertens JR, et al. Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: Comparison with matched controls. Archives of Internal Medicine. 2003;163(20):2511–2517. [PubMed]
  • Nunes E, Hasin D, Blanco C. Substance abuse and psychiatric comorbidity—Overview of diagnostic methods, diagnostic criteria, structured and semi-structured interviews, and biological markers. In: Kranzler HR, Tinsley JA, editors. Dual Diagnosis and Treatment: Substance Abuse and Comorbid Disorders. New York: Marcel Dekker; 2004. pp. 61–101.
  • Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. Journal of the American Medical Association. 2004;291(15):1887–1896. [PubMed]
  • Peters RH, et al. Effectiveness of screening instruments in detecting substance use disorders among prisoners. Journal of Substance Abuse and Treatment. 2000;18(4):349–358. [PubMed]
  • Pierucci-Lagha A, et al. Diagnostic reliability of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) Drug and Alcohol Dependence. 2005;80(3):303–312. [PubMed]
  • Pierucci-Lagha A, et al. Reliability of DSM-IV diagnostic criteria using the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) Drug and Alcohol Dependence. 2007;91(1):85–90. [PMC free article] [PubMed]
  • Pull CB, et al. Concordance between ICD-10 alcohol and drug use disorder criteria and diagnoses as measured by the AUDADIS-ADR, CIDI and SCAN: Results of a cross- DADIS-cross-national study. Drug and Alcohol Dependence. 1997;47(3):207–216. [PubMed]
  • Regier DA, et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) Study. Journal of the American Medical Association. 1990;264(19):2511–2518. [PubMed]
  • Robinson TE. Addicted rats. Science. 2004;305(5686):951–953. [PubMed]
  • Rogalski CJ. Factor structure of the Addiction Severity Index in an inpatient detoxification sample. International Journal of Addiction. 1987;22(10):981–992. [PubMed]
  • Ross HE, et al. Diagnosing comorbidity in substance abusers: A comparison of the test-retest reliability of two interviews. American Journal of Drug and Alcohol Abuse. 1995;21(2):167–185. [PubMed]
  • Rubio-Stipec M, Peters L, Andrews G. Test-retest reliability of the computerized CIDI (CIDI-Auto): Substance abuse modules. Substance Abuse. 1999;20(4):263–272. [PubMed]
  • Schuckit MA, et al. A comparison of DSM-III-R, DSM-IV and ICD-10 substance use disorders diagnoses in 1922 men and women subjects in the COGA study: Collaborative Study on the Genetics of Alcoholism. Addiction. 1994;89(12):1629–1638. [PubMed]
  • Schuckit MA, et al. Five-year clinical course associated with DSM-IV alcohol abuse or dependence in a large group of men and women. American Journal of Psychiatry. 2001;158(7):1084–1090. [PubMed]
  • Schuckit MA, et al. A 5-year prospective evaluation of DSM-IV alcohol dependence with and without a physiological component. Alcoholism: Clinical and Experimental Research. 2003;27(5):818–825. [PubMed]
  • Spitzer RL. Psychiatric diagnosis: Are clinicians still necessary? Comprehensive Psychiatry. 1983;24(5):399–411. [PubMed]
  • Spitzer RL, Fleiss JL. A re-analysis of the reliability of psychiatric diagnosis. British Journal of Psychiatry. 1974;125(0):341–347. [PubMed]
  • Spitzer RL, Endicott J, Robins E. Clinical criteria for psychiatric diagnosis and DSM-III. American Journal of Psychiatry. 1975;132(11):1187–1192. [PubMed]
  • Tapper AR, et al. Nicotine activation of alpha 4* receptors: Sufficient for reward, tolerance, and sensitization. Science. 2004;306(5698):1029–1032. [PubMed]
  • Torrens M, et al. Diagnosing comorbid psychiatric disorders in substance abusers: Validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. American Journal of Psychiatry. 2004;161(7):1231–1237. [PubMed]
  • Weisner C, McLellan AT, Hunkeler EM. Addiction Severity Index data from general membership and treatment samples of HMO members: One case of norming the ASI. Journal of Substance Abuse and Treatment. 2000;19(2):103–109. [PubMed]
  • Wiesbeck GA, et al. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction. 1996;91(10):1469–1478. [PubMed]
  • Williams JB, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Archives of General Psychiatry. 1992;49(8):630–636. [PubMed]
  • Wittchen HU, et al. Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI) Social Psychiatry and Psychiatric Epidemiology. 1998;33(11):568–578. [PubMed]
  • Wittchen HU, Kessler RC. Modifications of the CIDI in the National Comorbidity Survey: The development of the UM-CIDI [NCS Working Paper 2] Ann Arbor, MI: National, Comorbidity Survey; 1994.
  • World Health Organization. ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research (Volume II) Geneva, Switzerland: World Health Organization; 1993.
  • Zanarini MC, et al. The Collaborative Longitudinal Personality Disorders Study: Reliability of Axis I and II diagnoses. Journal of Personality Disorders. 2000;14(4):291–299. [PubMed]
  • Zanis DA, et al. Reliability and validity of the Addiction Severity Index with a homeless sample. Journal of Substance Abuse and Treatment. 1994;11(6):541–548. [PubMed]
  • Zanis DA, McLellan AT, Corse S. Is the Addiction Severity Index a reliable and valid assessment instrument among clients with severe and persistent mental illness and substance abuse disorders? Community Mental Health Journal. 1997;33(3):213–227. [PubMed]
Articles from Addiction Science & Clinical Practice are provided here courtesy of
BioMed Central